Research brief · 2026-09-09
How Much of the Weight Lost on GLP-1s Is Muscle?
Semaglutide, tirzepatide, liraglutide and dulaglutide are prescription medications approved for type 2 diabetes and, in some cases, chronic weight management. A common worry is that the weight they help people lose is partly muscle. A 2026 systematic review in the Annals of Internal Medicine is the best attempt so far to put a number on it.
Batsis and colleagues screened 8,102 papers and found 35 randomized controlled trials reporting body composition for these drugs. Median trial length was 26 weeks and median size was 78 participants. Across those trials, the median share of total weight loss attributable to muscle-related measures was 28.3%, with an interquartile range from 15.9% to 39.9%. The reviewers had set a benchmark of roughly 25% beforehand, the share you would expect from weight loss generally, and 65% of the drug studies exceeded it.
Measurement method mattered. Trials using bioimpedance or DXA scans reported a median of about 29% with a wide range, while trials using CT or MRI, the more precise methods, reported about 25% with a much tighter range. Some of the alarming high-end numbers may be measurement artifact rather than biology.
The context most coverage skips: 38% of the comparison groups, people losing weight through lifestyle or placebo, also exceeded the muscle-loss benchmark. Losing lean tissue alongside fat is a general feature of weight loss. These drugs produce more total weight loss, and therefore more absolute lean loss, rather than uniquely destroying muscle.
The limits are large. The authors could not pool the numbers statistically because methods varied too much, and fewer than half the trials were rated low risk of bias. "Fat-free mass" includes water and organ tissue, not just contractile muscle. And not one of the 35 trials measured grip strength, gait speed or any physical function. Whether protein intake or resistance training changes the outcome has not been tested in this population. Questions about these medications belong with a physician.
Sources
- Batsis JA et al., Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
- Annals of Internal Medicine 2026
- Arslan S, Medical nutrition in the GLP-1 era: protein strategies and lean mass preservation
- Clinical Nutrition ESPEN 2026
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.